Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of CVRX is 12 and suggests 135% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell